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Abstract Children of minor parents are under-represented
in clinical trials. This is largely because of the ethical,
legal, and regulatory complexities in the enrolment, con-
sent, and appropriate access of children of minor parents to
clinical research. Using a case-based approach, we exam-
ine appropriate access of children of minor parents in an
international vaccine trial. We first consider the scientific
justification for inclusion of children of minor parents in a
vaccine trial. Laws and regulations governing consent
generally do not address the issue of minor parents. In their
absence, local community and cultural contexts may
influence consent processes. Rights of the minor parent
include dignity in their role as a parent and respect for their
decision-making capacity in that role. Rights of the child
include the right to have decisions made in their best
interest and the right to the highest attainable standard of
health. Children of minor parents may have vulnerabilities
related to the age of their parent, such as increased rates of
poverty, that have implications for consent. Neuroscience
research suggests that, by age 12–14 years, minors have
adult-level capacity to make research decisions in situa-
tions with low emotion and low distraction. We conclude
with a set of recommendations based on these findings to
facilitate appropriate access and equity related to the par-
ticipation of children of minor parents in clinical research.
This article is part of the topical collection on Ethics of Pediatric Drug
Research.
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Key Points
Excluding the children of minor parents from clinical
trials raises issues of appropriate access and equity.
Minor parents should be involved in making
decisions on research consent for their children.
There are circumstances in which consent of an
additional adult may be appropriate.
1 Introduction
Current approaches to pediatric research focus on ‘‘ap-
propriate access,’’ recognizing the tension between pro-
tecting children from potential harms, and providing access
to benefits [1, 2]. For individual children, these include
access to new treatments, and, for children as a group,
expanding our knowledge of childhood disease, effective
treatments, and improved health outcomes. The European
Union’s Clinical Trials Directive states that ‘‘… medicinal
products which are likely to be of significant clinical value
for children are fully studied. The clinical trials required
for this purpose should be carried out under conditions
affording the best possible protection for the subjects’’ [1].
Appropriate access has been framed as an issue of health
equity [3].
Children of minor parents are a group that raises par-
ticularly complex ethical questions. These children are
often under-represented, and there is little guidance
regarding their enrolment in clinical trials. Children overall
are considered a vulnerable population; children of minor
parents may have additional vulnerabilities stemming from
the age, developmental status, and socioeconomic condi-
tions of their minor parents. The participation of children
of minor parents in clinical research raises two important
ethical questions: (1) should this potentially more vulner-
able group of children participate in research, and (2) if so,
who should consent to their participation?
This manuscript provides a review and discussion of the
ethical considerations for the participation of children of
minor parents in clinical trials. Using a case-based
approach, we first consider the scientific justification for
inclusion of children of minor parents, legal issues related
to inclusion, and the community and cultural contexts. We
then discuss appropriate access and equity, the balance
between the rights of the minor parent and the rights of the
child, the vulnerability of the child, and decision-making
capacity of the minor parent. We provide a set of points to
consider for appropriate access of children of minor parents
to clinical research.
2 Case Description and Approach: The COMPAS
Study
The COMPAS (Clinical Otitis Media and Pneumonia Study)
was a phase III randomized double-blind controlled clinical
trial of a pneumococcal conjugate vaccine conducted among
24,000 infants living in Panama, Argentina, and Colombia
[4]. Although currently standard of care [5], pneumococcal
conjugate vaccines were still in development at the time of
the trial initiation in 2007. The COMPAS protocol, in
accordance with international guidance [6], required that
informed consent for children be obtained according to local
law and be approved by the local ethics committee. However,
the relevant local laws were not straightforward, and no
specific law or guidance specified what to do when the con-
senting parent was a minor.
At the start of COMPAS in Panama, the ethics com-
mittee permitted minor parents to give research consent for
their children, as for consent for children of adult parents.
During the study, as part of a routine review, the local
ethics committee changed its policy and asked that an adult
(aged 18 years or older) provide an additional consent,
beyond that of the minor parent. This additional adult could
be the other parent (if over 18 years) or a grandparent. The
minor parent was asked to re-consent alone for the child
when the minor parent reached 18 years.
Post-trial analyses showed that COMPAS under-enrolled
children of minor parents. In Panama, of 65,000 live births
annually, approximately 20% are to mothers aged under
18 years, of which 80% are in the age group 16–17 years [7].
Despite this high proportion of minor parents in Panama, of
approximately 7200 infant participants in COMPAS in
Panama, only 211 children (3%) had a minor parent provide
consent, raising the question of whether children of minor
parents had appropriate trial access.
In response to the ethical challenges faced by investi-
gators conducting COMPAS, an international panel of
volunteer experts (pediatrics and adolescent medicine,
clinical trials, psychology, ethics, industry, medical gov-
ernance) reviewed relevant literature and ethics guidelines
to come to a consensus. We limited discussion to minor
parents aged 14–17 years because, in most countries,
18 years is the age of legal adulthood, and minor parents
aged 12–13 years represent a tiny but distinct group with
respect to cognition, development, and legal status [8].
3 Scientific Justification
International guidance requires that the inclusion of chil-
dren in clinical research be justified scientifically [9].
Worldwide, pneumonia accounts for 15% of deaths in
children aged under 5 years [10], making it an important
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World Health Organization (WHO) target [11]. Children in
poverty are disproportionately represented in pneumonia
deaths because they have an increased risk of exposure to,
and severity of, pneumococcal disease [12]. This risk is
attributable to poor nutrition, less access to medical care,
indoor air pollution from biomass fuels, overcrowding, and
(potentially) immune response difference in children living
in conditions of poverty [12].
The inclusion of children of minor parents in the COM-
PAS study was supported by the potential preventive effect of
a pneumococcal vaccine. Compared with children of adult
parents, children of minor parents experience higher rates of
negative child health outcomes and higher rates of infant
mortality from diseases such as pneumonia [13–17]. Because
of these disparities, the children of minor parents constitute an
important target population for pneumococcal vaccines.
When children of minor parents comprise a large and
distinct group within a population, exclusion might result in
scientific bias. This is a concern with phase III and IV trials,
which are intended to provide a broad population basis
regarding the safety and efficacy of an intervention. This is
particularly relevant in parts of sub-Saharan Africa, where the
proportion of women aged 15–19 years giving birth is
30–50%, or in many Latin American and Caribbean coun-
tries, where it is 10–25% [18]. In the case of COMPAS, a
more equitable inclusion of children of minor parents might
have strengthened the generalizability of the trial.
4 Legal Issues Related to Minor Parent Consent
Informed consent is a voluntary decision to take part in
research after being informed of the nature, significance,
implications, and risks of the research, by a person legally
capable of giving consent [1]. Assent is an affirmative
agreement to participate in research after being informed
about research procedures, risks, and benefits [19]. Assent
is obtained when an individual has some degree of capacity
to understand the research and make decisions, but does not
have the legal authority to provide informed consent. For
research with children, parents typically provide informed
consent and children (over about 7 years of age) provide
assent. This process is less clear when the parent is a minor.
Guidance for research with children requires that con-
sent procedures follow local laws [6, 20], yet few countries
have laws specific to consent from parents who are them-
selves minors. When there are no laws on research consent,
research often follows laws for medical consent. Laws
regarding medical decision-making authority and consent
for children vary among and within countries [21]. Some
countries clearly define the legal medical decision maker
for the child of a minor parent. This authority might be
given to the minor parent, to an adult family member (e.g.,
grandparent), or the other parent (if not a minor). Minor
parents who are the heads of households and minors who
are married may additionally be considered to have med-
ical decision-making authority for their child. However, it
is unclear how medical decision-making authority trans-
lates into research decision-making authority.
In the absence of laws governing medical consent for
children of minor parents, there are differences based upon
traditions, culture, or common practices. In some places,
such as the USA, minor parents are assumed to have the
same rights with respect to medical decisions for their child
as adult parents. In contrast, in Panama and in most African
settings, the child’s grandparents or a head of household
frequently make decisions.
While not directly applicable to the children of minor
parents, laws regarding minors’ medical consent for them-
selves may provide insight as to whether minors are generally
given the right to consent, and indirectly, whether minors are
believed to have the capacity to consent. Research ethics
guidelines consider as children those who have not reached
legal adulthood in their country (usually 18 years of age) (see,
for example, The Council for International Organizations of
Medical Sciences [CIOMS] [6] and US FDA regulations
[22]). In many countries, minors aged under 18 years may
consent for their own medical care in specific circumstances
[23], and minors who may consent to clinical care are gen-
erally allowed to consent to research on the topic (e.g., HIV
prevention [24]). For example, UK law defines a minor as
being aged under 16 years for medical treatment and
research, although the typical legal age of adulthood is
18 years. In the UK, the test of ‘‘Gillick competence’’ pro-
vides a legal basis for minors aged under 16 years to provide
their own consent as long as they demonstrate the ability to
understand the procedures involved and the consequences
[25]. Recent UK research guidelines suggest that ‘‘Gillick
competence’’ could also be applied to clinical research [25].
In the countries of the COMPAS study, the legal age of
adulthood is 18 years, although children may be considered
emancipated from their parents at 16 years in Panama and at
13–16 years in other Latin American countries [26].
In the COMPAS trial, the lack of specific laws for
research or medical consent for children of minor parents
created uncertainty and likely acted as an additional barrier
to participation. When laws are unclear, investigators,
sponsors, and ethics review committees must draw on
ethical considerations in specifying consent approaches.
5 Community Practices and Norms
The Declaration of Helsinki recognizes the ethical importance
of respecting local laws and practices [9]. Benchmarks for
international research include ensuring community
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engagement and seeking community permission [6]. For
example, in malaria clinical trials in Ghana and Mali, there
were detailed community studies, engagement meetings, and
ultimately community permission. These practices facilitated
the process of individual informed consent [27, 28]. The
rationale for changes in the consent process for the COMPAS
trial was to achieve greater consistency with community
norms in which the grandparent frequently assumes respon-
sibility for the child of the minor parent.
6 The Rights of the Minor Parent and the Rights
of the Child
Investigators, sponsors, and ethics committees need to
balance the emerging capacity of adolescents for autono-
mous decision making with the need for special protections
due to their minor status [29]. With regard to minor par-
ents, this encompasses respect for the minor parent’s role in
decision making for their child.
Rights of parents stem from multiple sources, including
local laws, community practices, and ethical justifications
[30]. Conceptually, parental rights have been linked to the
responsibilities and duties of the parent toward the child [30].
Parents are responsible for the welfare and healthy develop-
ment of the child and have the right to make decisions for
their child regarding topics such as diet, schooling, religion,
and healthcare. Laws regarding parental authority generally
do not specify a lower age limit. Minor parents are thus
generally afforded the same legal rights as adult parents,
including the right to make healthcare decisions for their
child. Ethical justifications for parental rights include the
assumption that parents generally make decisions in the best
interest of the child. Assuming that the minor parents are
fulfilling their responsibilities for caring for the child, we
should recognize minor parents’ rights to make decisions.
Children of minor parents also have rights. The Con-
vention on the Rights of the Child asserts the primary
importance of the child’s right to have decisions made in
their best interest (Article 3, paragraph 1) and goes on to
affirm the child’s right to the highest attainable standard of
health (Article 24, paragraphs 1 and 4) [31]. Parental
decision-making rights are necessarily limited by these
rights of the child. Parental rights also might be limited by
law (e.g., child abuse laws), incapacity of the parent, and
cultural practices and norms [30, 31].
7 Vulnerability
One ethical question raised by COMPAS and other pedi-
atric clinical trials is whether the children of minor parents
have additional vulnerabilities related to research
participation in comparison with children of adult parents.
The Declaration of Helsinki defines vulnerability as ‘‘an
increased likelihood of being wronged or of incurring
additional harm’’ [9]. We consider vulnerability to be a set
of characteristics and/or situations that may make an
individual more likely to be wronged or experience harm
[32]. Children are considered a vulnerable population in
research and in need of additional protections. Child
research participants may be vulnerable in multiple ways;
for example, they may lack decisional capacity or be def-
erential to authority; they may be subject to the legal
authority of others; and/or they may be socioeconomically
disadvantaged, or otherwise belong to a group whose rights
and interests are undervalued by society [33].
Special protections for children are codified in most human
subject research guidance, such as CIOMS and the US Code of
Federal Regulations (CFR 50) [6, 22]. For children, interna-
tional guidance documents require additional justification for
their inclusion. For example, the Declaration of Helsinki states
that researchwithvulnerablepopulations is only justified ‘‘if the
research is responsive to the health needs and priorities of this
population or community and if there is a reasonable likelihood
that this population or community stands to benefit from the
results of the research [9].’’ TheCOMPAS trial tested a vaccine
for pneumococcus, and pneumonia is a common cause of death
that disproportionately affects children in high poverty settings
[34]. Thus, children of minor parents stood to benefit from the
trial. For a study to recruit from a vulnerable group, the specific
type and degree of vulnerability, the risks of the research pro-
tocol, and the protections that can be put in place should all be
considered [35].
Children of minor parents may have additional vulner-
abilities related to the age of their parent, and these addi-
tional vulnerabilities have implications for research
consent. Compared with children of adult parents, children
of minor parents are more likely to live in poverty with its
attendant risks, including less access to healthcare, lower
education of their parents, and a greater power differential
between the minor parent and the researcher [13–17].
Children of minor parents may be the product of child
marriage [13–15, 35], with its increased risk of intraper-
sonal violence and coercion, making it possible that a
married minor parent may not be able to make a voluntary,
non-coercive decision on behalf of their child [36].
8 Adolescent Decision-Making Capacity
When that parent is herself (or himself) a minor, it raises the
questionofwhether theminor parent has the capacity toprovide
permission. While a large body of data exists on adult capacity
to consent to research [37], there is almost none on minor
parents’ capacity to consent to research for their child.
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During adolescence, individuals develop decision-mak-
ing skills relevant to research, including the ability to
understand complex and abstract concepts, attend selec-
tively to information, accurately perceive risk, consider
multiple conflicting viewpoints, and logically weigh risks
and benefits [38–41]. Data from high-income countries
suggest that, by age 12–14 years, adolescents have similar
capacity to adults with regard to providing informed con-
sent, including adequate understanding, reasoning, and
evidence of choice [42–44]. Studies of adolescents’ clinical
trial decision-making capacity demonstrated that an ado-
lescent’s understanding of research concepts, such as ran-
domization, placebo, and experimental design is generally
similar to that described for adults [45–47].
Adolescent decision making differs from that of adults
in two key areas relevant to research consent. The first is
decision-making experience. Healthcare decision-making
competence is related, in part, to one’s experience making
these decisions. Compared with adults, most minors have
less healthcare decision-making experience. Assuming
medical decision making improves medical research deci-
sion making, minor parents who are actively making
medical decisions for their child will have more decision-
making experience than minors in general.
Second, while adolescents make decisions similar to
those of adults in situations that allow for logical, unhur-
ried reasoning, adolescents frequently have more difficulty
than adults in situations with high emotion or distraction
[38, 41]. In COMPAS, participants were consented in
settings with minimal distraction and with efforts taken to
ensure that participants understood and made an autono-
mous choice. Therefore, it is reasonable to assume that, in
such situations, the capacity of minor parents to make
research decisions for their child is similar to that of adults.
Additional decision supports may be needed for the safe
participation of children of minor parents in higher risk or
more complex research or when consent must be obtained
in sub-optimal situations (e.g., research in emergency set-
tings or with very sick children).
9 Appropriate Access and Equity
While pediatric guidance supports the inclusion of chil-
dren, the experience with COMPAS suggests that, for
clinical trials recruiting children of minor parents, inves-
tigators, sponsors, and ethics committees may need to
consider not only the rights and welfare of the individual
child for inclusion in clinical trials but also the need to
ensure health equity (see Fig. 1). A health equity per-
spective focuses on fair and proportionate representation
for vulnerable groups. A focus on appropriate access and
health equity represents the ongoing shift in paradigms
surrounding research with children: from research viewed
primarily from the perspective of its potential risks to
research viewed from a more balanced perspective that
includes its potential benefits.
Research guidelines (e.g., CIOMS and Declaration of
Helsinki) encourage the appropriate access, rather than the
exclusion, of populations under-represented in research
[6, 9]. Compared with adults, children in general are under-
represented in clinical trials, and regulatory guidance
increasingly encourages inclusion with additional attention
to safety, rather than exclusion (see, for example, Gill [48]
and US National Institutes of Health [49]). The COMPAS
experience suggests that children of minor parents may
have even less access to clinical trials. Ethical and regu-
latory guidance (for example, the FDA’s 21 CFR 50 [22]
and European Medicines Agency guidance on pediatric
clinical trials [50]) requires a consideration of trial risks,
direct trial benefits, and the balance of these risks and
benefits. This type of risk–benefit assessment favors
inclusion in trials such as COMPAS, in which the risks and
benefits are well understood based on previous pediatric
trials or adult studies. In the COMPAS study, children of
minor parents stood to benefit to the same extent as chil-
dren of adult parents.
Well-designed clinical trials may also provide benefits
beyond the direct benefits of the intervention or medica-
tion. In many low-resource settings in which neither the
resources nor the health infrastructure are available to
provide universal access to high-quality general pediatric
care, research participation gives both the child and their
minor parent access to research personnel, medical per-
sonnel, and health facilities. This indirect benefit raises
ethical concerns: the lack of access to care creates vul-
nerability because research decisions might be made not on
the risk–benefit assessment of the intervention but rather on
the basis of enhanced access to medical care [35]. This is a
particular concern for children of minor parents because of
their higher rates of poverty. Investigators, sponsors, and
ethics committees need to acknowledge and manage this
potential vulnerability [51].
10 Discussion and Points to Consider
Our review of ethical guidance and data on decision-
making capacity suggests that children of minor parents
ought to be included in clinical research when it concerns
health issues relevant to them, with the following points
warranting consideration:
1. While international research documents advise inves-
tigators and sponsors to follow local law with respect
to minor parent consent, if local law is silent, vague, or
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does not specifically address minor parents’ ability to
consent for their child, investigators and sponsors
should work with local institutions, ethics committees,
and community stakeholders to understand the cul-
tural, normative, and ethical contexts.
2. Minor parents should be involved in the decision-
making process for their child. This demonstrates
respect for the young person as a parent and for their
decision-making capacity.
3. An additional adult consent procedure to supplement
consent by the minor parent should only be included if
it does not interfere with the dignity of the parental
role of the minor parent or if it is required by local law.
It should presume one or more of the following:
(a) the minor parent lacks legal standing as the
medical decision maker for the child;
(b) it is an established cultural practice for another
adult in the child’s life (e.g., a grandparent or head
of household) to provide medical consent and make
decisions regarding the child’s welfare; and/or
(c) it has been demonstrated that the minor parent
lacks the decision-making capacity to consent for
the child.
In the absence of one of these three situations, then the
minor parent should provide consent.
4. Given the characteristics and nature of an adolescent’s
evolving capacity to consent, the following should be
considered:
(a) information must be presented in a way that
fosters dialogue and considers that adolescents
may be more deferential than adults and less
willing to ask questions or refuse participation;
(b) additional safeguards may be needed for research
in which there may be distractions or high
emotions during the consent process, such as
research with very sick children;
(c) additional protections may be needed when
consenting for higher risk protocols to ensure
that research is adequately understood.
5. The design and execution of the consent process and
research procedures should support or mitigate any
vulnerabilities that are more typically seen in children
of minor parents. These might include those stemming
from the minor parents’ developmental status, deci-
sion-making capacity, literacy level, poverty, legal
rights, and cultural contexts.
6. Investigators, sponsors, and ethics review committees
should consider community engagement processes to
better understand the roles, rights, and responsibilities
of the minor parent with respect to their child, taking
into consideration prevailing social, cultural, and
traditional contexts.
Sponsors, investigators, and ethics committees have a
responsibility to carefully consider the access of children of
minor parents to clinical trials and ensure, as appropriate,
opportunities to participate in research. Government regu-
latory agencies should also consider addressing this
Fig. 1 Key ethical issues for
children of minor parents
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pediatric population when developing guidance for clinical
trials.
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